TENX News and Press, Tenax Therapeutics Inc. From 06/10/21

Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, is set to join the Russell Microcap® Index at the conclusion ...

Tenax Therapeutics (TENX): Q1 GAAP EPS of -$1.64 misses by $1.43.Cash, cash equivalents and marketable securities of $4M.Press Release For further details see: Tenax Therapeutics EPS misses by $1.43

Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today reported financial results for the first quarter of 2021 and...

Gainers: Celcuity (CELC) +43%.NCS Multistage (NCSM) +39%.MEDIROM Healthcare Technologies (MRM) +31%.Natuzzi (NTZ) +24%.Affimed (AFMD) +23%.Tenax Therapeutics (TENX) +23%.Brooklyn ImmunoTherapeutics (BTX) +20%.GT Biopharma (GTBP) +16%.Sohu.com (SOHU) +15%.fuboTV (...

Gainers: Celcuity (CELC) +56%, GeoVax Labs (GOVX) +36%, Affimed (AFMD) +24%, Tenax Therapeutics (TENX) +22%, Genetic Technologies (GENE) +13%.Losers: Novo Integrated Sciences (NVOS) -24%, Provention Bio (PRVB) -21%, Virpax ...

Tenax Therapeutics, Inc. (NASDAQ: TENX) announced positive data from its Phase 2 HELP Study that evaluated levosimendan in patients with pulmonary hypertension and heart failure with preserved ejection fraction.  Levosimendan Improves Hemodynamics and Exercise Tolerance i...

Are Analysts Right About These Penny Stocks? Penny stocks are some of the highest-risk stocks in the market. Thanks to a long history of volatility, manipulation, hype, and speculation, traders seek the ultimate alpha in these cheap shares. But it isn’t just for “wild west...

Tenax Therapeutics (TENX) surge 12% premarket after announcing positive data from the Phase 2 HELP Study that evaluated levosimendan in patients with pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF).This 6-week study design evaluated invasive card...

Celcuity (CELC) +55% on licensing agreement up to $340M for breast cancer treatment gedatolisib.Affimed N.V. (AFMD) +29% on positive data from NK cells + AFM13 in solid tumors.Greenwich LifeSciences (GLSI) +29% on robust immune response Phase IIb data in breast cancer.Gulf Reso...

84% of PH-HFpEF patients responded to levosimendan based on prespecified criteria in the initial open-label lead-in phase Levosimendan improved cardiovascular hemodynamics and exercise capacity in PH-HFpEF patients Levosimendan produced a significant improvement in 6...